CN112469429B - Ccr5抑制剂在癌症治疗中的应用 - Google Patents

Ccr5抑制剂在癌症治疗中的应用 Download PDF

Info

Publication number
CN112469429B
CN112469429B CN201980047951.5A CN201980047951A CN112469429B CN 112469429 B CN112469429 B CN 112469429B CN 201980047951 A CN201980047951 A CN 201980047951A CN 112469429 B CN112469429 B CN 112469429B
Authority
CN
China
Prior art keywords
ccr5
seq
cancer
administered
ccr5 inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980047951.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN112469429A (zh
Inventor
O·哈特利
R·E·奥福德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orion Biotechnology Switzerland SARL
Original Assignee
Orion Biotechnology Switzerland SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Biotechnology Switzerland SARL filed Critical Orion Biotechnology Switzerland SARL
Publication of CN112469429A publication Critical patent/CN112469429A/zh
Application granted granted Critical
Publication of CN112469429B publication Critical patent/CN112469429B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN201980047951.5A 2018-05-28 2019-05-24 Ccr5抑制剂在癌症治疗中的应用 Active CN112469429B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862677114P 2018-05-28 2018-05-28
US62/677,114 2018-05-28
US201962792600P 2019-01-15 2019-01-15
US62/792,600 2019-01-15
PCT/IB2019/054350 WO2019229616A1 (en) 2018-05-28 2019-05-24 Ccr5 inhibitor for use in treating cancer

Publications (2)

Publication Number Publication Date
CN112469429A CN112469429A (zh) 2021-03-09
CN112469429B true CN112469429B (zh) 2025-02-14

Family

ID=67480241

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980047951.5A Active CN112469429B (zh) 2018-05-28 2019-05-24 Ccr5抑制剂在癌症治疗中的应用

Country Status (11)

Country Link
US (1) US20210205411A1 (https=)
EP (1) EP3813870B1 (https=)
JP (2) JP7319020B2 (https=)
KR (1) KR20210016398A (https=)
CN (1) CN112469429B (https=)
AU (1) AU2019276939A1 (https=)
BR (1) BR112020024328A2 (https=)
CA (1) CA3101556A1 (https=)
MX (1) MX2020012782A (https=)
WO (1) WO2019229616A1 (https=)
ZA (1) ZA202007955B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021019405A2 (pt) * 2019-04-01 2021-11-30 Cytodyn Inc Agentes anti-ccr5 e métodos de tratamento que bloqueiam a metástase do câncer ou aumentam a morte celular induzida pela quimioterapia prejudicial ao dna
WO2021231648A2 (en) * 2020-05-12 2021-11-18 Gigagen, Inc. Cancer therapeutics comprising chemokine or its analog
WO2024146707A1 (en) * 2023-01-06 2024-07-11 Université De Genève Variant ligand conjugates for payload delivery
WO2025172252A1 (en) 2024-02-15 2025-08-21 Novo Nordisk A/S Protracted ccr5 antagonists and uses thereof
WO2025176787A1 (en) * 2024-02-22 2025-08-28 Orion Biotechnology Holding Sa Ccl5 variants for modulating gpr75

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101511867A (zh) * 2006-07-25 2009-08-19 明塔卡医学研究基金会 细胞因子衍生物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32808A (es) * 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
US8916696B2 (en) * 2011-06-12 2014-12-23 City Of Hope Aptamer-mRNA conjugates for targeted protein or peptide expression and methods for their use
ES2800316T3 (es) * 2011-06-13 2020-12-29 Tla Targeted Immunotherapies Ab Tratamiento del cáncer
JP6518585B2 (ja) * 2012-05-14 2019-05-22 リチャード ジー． ペステル がんの治療のためのｃｃｒ５の修飾薬の使用
US20150250837A1 (en) * 2012-09-20 2015-09-10 Morningside Technology Ventures Ltd. Oncolytic virus encoding pd-1 binding agents and uses of the same
EP3212228B1 (en) * 2014-10-27 2025-12-03 Ruprecht-Karls-Universität Heidelberg Maraviroc alone or in combination therapy for the treatment of cancer
AR105654A1 (es) * 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101511867A (zh) * 2006-07-25 2009-08-19 明塔卡医学研究基金会 细胞因子衍生物

Also Published As

Publication number Publication date
CN112469429A (zh) 2021-03-09
JP2021525770A (ja) 2021-09-27
CA3101556A1 (en) 2019-12-05
EP3813870A1 (en) 2021-05-05
EP3813870C0 (en) 2023-11-15
BR112020024328A2 (pt) 2021-02-23
WO2019229616A1 (en) 2019-12-05
MX2020012782A (es) 2021-04-28
KR20210016398A (ko) 2021-02-15
EP3813870B1 (en) 2023-11-15
ZA202007955B (en) 2022-06-29
JP7319020B2 (ja) 2023-08-01
JP2023134704A (ja) 2023-09-27
US20210205411A1 (en) 2021-07-08
AU2019276939A1 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
CN112469429B (zh) Ccr5抑制剂在癌症治疗中的应用
JP7712990B2 (ja) 血小板由来成長因子受容体アルファの遺伝的異常に関連する癌の治療のための、１－［４－ブロモ－５－［１－エチル－７－（メチルアミノ）－２－オキソ－１，２－ジヒドロ－１，６－ナフチリジン－３－イル］－２－フルオロフェニル］－３－フェニルウレアおよびアナログの使用
AU2024205010B2 (en) CSF1R inhibitors for use in treating cancer
US20180028531A1 (en) Use of plinabulin in combination with immune checkpoint inhibitors
CN110996952A (zh) 用于治疗癌症的方法
EP3092250A1 (en) Polynucleotides for the in vivo production of antibodies
CN110494161A (zh) 用于治疗癌症的抗pd-l1抗体和dna-pk抑制剂的组合
KR20190130644A (ko) 항암 조합 요법
AU2017305502B2 (en) Combination of glucagon receptor antagonists and PI3K pathway inhibitors for the treatment of cancer
AU2019206652B2 (en) Deuterated compounds, compositions, and methods for treating cancers associated with ETBR activation
AU2020343329C1 (en) Methods of treatment
US20250186446A1 (en) Organic compounds
US20240000883A1 (en) Method of sensitizing cancers to immunotherapy using immunomodulatory agents
HK40048943A (en) Ccr5 inhibitor for use in treating cancer
RU2822394C1 (ru) Способы лечения
BR112017016902B1 (pt) Composição farmacêutica, respectivo uso e uso de plinabulina

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40048943

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant